1. Freedman JR, Markert MS, Cohen AJ: Primary and secondary lacrimal canaliculitis: A review of literature. Surv Ophthalmol56(4):336-347, 2011. doi: 10.1016/j.survophthal.2010.12.001
2. Orbit, Eylids and Lacrimal System, Section 7. Basic and Clinical Science Course, AAO, 2022-2023.
3. Mills DM, Bodman MG, Meyer DR, Morton AD 3rd. The microbiologic spectrum of dacryocystitis: a national study of acute versus chronic infection. Ophthal Plast Reconstr Surg. 2007
Jul-Aug. 23(4):302-6.
4. Chandler JR, Langenbrunner DJ, Stevens ER. The pathogenesis of orbital complications in acute sinusitis. Laryngoscope 1970; 80:1414-28.
5. Davies BW, Smith JM, Hink EM, Durairaj VD. C-Reactive Protein As a Marker for Initiating Steroid Treatment in Children With Orbital Cellulitis. Ophthalmic Plast Reconstr Surg. 2015
Sep-Oct;31(5):364-8. doi: 10.1097/IOP.0000000000000349. PMID: 25393908.
6. Basic and Clinical Science Course 2019-2020: Oculofacial Plastic and Orbital Surgery. San Francisco, CA: American Academy of Ophthalmology; 2019.
OKÜLER YÜZEY ENFEKSİYONLAR
KAYNAKLAR
1. Kömür B, Erdoğan Dib N, Bilgin AB (çevirenler). Bölüm 4. Oküler Yüzey Hastalıkları: Ana Kavramlar ve Viral Enfeksiyonlar. American Academy of Ophthalmology (Çeviri Ed: Aydın
O’Dywer P). Yüzey Hastalıkları ve Kornea. Cilt 8. 2010-2011: 95-130.
2. Feder RS, Berdy GJ, Iurno JD et al. Chapter 12, Infectious Diseases of the Cornea and External Eye: Bacterial, Fungal, and Parasitic Infections. American Academy of Ophthalmology Basic
and Clinical Science Course, Section 08: External Disease and Cornea. 2022-2023: 317-351.
3. Ünal M, Konuk O. Göz Kapakları ve Hastalıkları Bölüm 16. Editörler: Aydın O’Dywer P ve Akova Y. Temel Göz Hastalıkları. 3. Baskı, Ankara: Güneş Kitapevi 2015: 157-182
4. Feder RS, Berdy GJ, Iurno JD et al. Chapter 3, Clinical Approach to Ocular Surface Disease. American Academy of Ophthalmology Basic and Clinical Science Course, Section 08: External
Disease and Cornea. 2022-2023: 47-85.
5. Salmon JF, Bölüm 2. Göz Kapakları. Çeviri Ed: Akova YA ve Dönmez O. Kanski Klinik Oftalmoloji. Sistematik Yaklaşım. 9.Baskı. Elsevier. Güneş Kitapevi, 2021: 38-97.
6. Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials. Ocul Surf. 2014 Oct;12(4):273-847. Willmann D, Guier CP, Patel BC, Melanson SW. Stye. 2023 Aug 8.
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
8. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014 Aug 15;90(4):229-35.
9. Feder RS, Berdy GJ, Iurno JD et al. Chapter 11, Infectious Diseases of the Cornea and External Eye: Viral Infections. American Academy of Ophthalmology Basic and Clinical Science Course,
Section 08: External Disease and Cornea. 2022-2023: 281-316
10. Rhee MK, Yeu E, Barnett M, et al. Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. Eye Contact Lens. 2023;49(8):311-318.
11. Feder RS, Berdy GJ, Iurno JD et al. Chapter 12, Infectious Diseases of the Cornea and External Eye: Bacterial, Fungal, and Parasitic Infections. American Academy of Ophthalmology Basic
and Clinical Science Course, Section 08: External Disease and Cornea. 2022-2023: 317-351.
12. Gurnani B, Badri T, Hafsi W. Phthiriasis Palpebrarum. [Updated 2023 Jun 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.
ncbi.nlm.nih.gov/books/NBK459226/
13. Alparslan FN, Konjonktiva Hastalıkları Bölüm 18. Editörler: Aydın O’Dywer P ve Akova Y. Temel Göz Hastalıkları. 3. Baskı, Ankara: Güneş Kitapevi 2015: 195-208.
14. Salmon JF, Bölüm 6. Konjonktiva. Çeviri Ed: Akova YA ve Dönmez O. Kanski Klinik Oftalmoloji. Sistematik Yaklaşım. 9.Baskı. Elsevier. Güneş Kitapevi, 2021: 167-201.
15. Cheema M, Aghazadeh H, Nazarali S, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). Can J Ophthalmol. 2020;55(4):e125-e129.
16. Salmon JF, Bölüm 7 Kornea. Çeviri Ed: Akova YA ve Dönmez O. Kanski Klinik Oftalmoloji. Sistematik Yaklaşım. 9.Baskı. Elsevier. Güneş Kitapevi, 2021: 203-273.
17. Akova YA, Yaycıoğlu RA, Kornea Hastalıklarına Giriş, Kornea İltihapları, Diğer Keratitler Bölüm 18. Editörler: Aydın O’Dywer P ve Akova Y. Temel Göz Hastalıkları. 3. Baskı, Ankara: Güneş
Kitapevi 2015: 235-259.
18. Hoffman JJ, Arunga S, Mohamed Ahmed AHA, Hu VH, Burton MJ. Management of Filamentous Fungal Keratitis: A Pragmatic Approach. J Fungi (Basel). 2022 Oct 11;8(10):1067.
ÖN SEGMENT ENFEKSİYONLARI
KAYNAKLAR
1. Anwar Z, Galor A, Albini TA, Miller D, Perez V, Davis JL. The diagnostic utility of anterior chamber paracentesis with polymerase chain reaction in anterior uveitis. Am J Ophthalmol.
2013;155(5):781-786. doi:10.1016/j.ajo.2012.12.008
2. Van der Lelij A, Ooijman FM, Kijlstra A, Rothova A. Anterior uveitis with sectoral iris atrophy in the absence of keratitis: a distinct clinical entity among herpetic eye diseases. Ophthalmology.
2000;107(6):1164-1170. doi:10.1016/s0161-6420(00)00115-9
3. Jap, Alizaa,b; Chee, Soon-Phaika,c,d. Viral anterior uveitis. Current Opinion in Ophthalmology 22(6):p 483-488, November 2011. | DOI: 10.1097/ICU.0b013e32834be021
4. Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Herpes Simplex Virus Anterior Uveitis. Am J Ophthalmol. 2021;228:231-236. doi:10.1016/j.
ajo.2021.03.053
5. Wensing B, Relvas LM, Caspers LE, et al. Comparison of rubella virus- and herpes virus-associated anterior uveitis: clinical manifestations and visual prognosis. Ophthalmology.
2011;118(10):1905-1910. doi:10.1016/j.ophtha.2011.03.033
6. Dawson CR, Togni B. Herpes simplex eye infections: clinical manifestations, pathogenesis and management. Surv Ophthalmol. 1976;21(2):121-135. doi:10.1016/0039-6257(76)90090-4
7. Tugal-Tutkun I, Otük-Yasar B, Altinkurt E. Clinical features and prognosis of herpetic anterior uveitis: a retrospective study of 111 cases. Int Ophthalmol. 2010;30(5):559-565. doi:10.1007/
s10792-010-9394-8
8. Draeger J. 1984. Differential diagnosis and monitoring of herpetic keratitis, p 133–139 In Blodi FC. (ed), Corneal sensitivity measurement and clinical importance. Springer-Verlag, New York,
NY
9. Sungur G, Hazirolan D, Yalvac I, et al. Incidence and prognosis of ocular hypertension secondary to viral uveitis. Int Ophthalmol. 2010;30:191-194.
10. Chan NS, Chee SP. Demystifying viral anterior uveitis: A review. Clin Exp Ophthalmol. 2019;47(3):320-333. doi:10.1111/ceo.13417
11. Batram M, Witte J, Schwarz M, et al. Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007-2018. Dermatol Ther (Heidelb).
2021;11(3):1009-1026. doi:10.1007/s13555-021-00535-7
12. Womack LW, Liesegang TJ. Complications of herpes zoster ophthalmicus. Arch Ophthalmol. 1983;101(1):42-45. doi:10.1001/archopht.1983.01040010044004
13. Marsh RJ, Cooper M. Ophthalmic herpes zoster. Eye (Lond). 1993;7 ( Pt 3):350-370. doi:10.1038/eye.1993.74
14. Chee SP, Jap A. Presumed fuchs heterochromic iridocyclitis and Posner-Schlossman syndrome: comparison of cytomegalovirus-positive and negative eyes. Am J Ophthalmol. 2008;146(6):883-
9.e1. doi:10.1016/j.ajo.2008.09.001
15. Chan NS, Chee SP, Caspers L, Bodaghi B. Clinical Features of CMV-Associated Anterior Uveitis. Ocul Immunol Inflamm. 2018;26(1):107-115. doi:10.1080/09273948.2017.1394471
16. Kreps EO, Derveaux T, De Keyser F, Kestelyn P. Fuchs’ Uveitis Syndrome: No Longer a Syndrome? Ocul Immunol Inflamm. 2016;24(3):348-357. doi:10.3109/09273948.2015.1005239
17. Kang H, Bao H, Shi Y, et al. Clinical Characteristics and Aqueous Humor Laboratory Analysis of Chinese Patients With Rubella Virus-Associated and Cytomegalovirus-Associated Fuchs
Uveitis Syndrome. Front Med (Lausanne). 2020;7:610341. Published 2020 Dec 18. doi:10.3389/fmed.2020.610341
18. De Groot-Mijnes JD, Rothova A, Van Loon AM, et al. Polymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J
Ophthalmol. 2006;141(2):313-318. doi:10.1016/j.ajo.2005.09.017
19. Chee SP, Bacsal K, Jap A, Se-Thoe SY, Cheng CL, Tan BH. Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. Am J Ophthalmol. 2008;145(5):834-840. do-
i:10.1016/j.ajo.2007.12.015
20. Chee SP, Jap A. Cytomegalovirus anterior uveitis: outcome of treatment. Br J Ophthalmol. 2010;94(12):1648–1652
ARKA SEGMENT ENFEKSİYONLARI
KAYNAKLAR
1. Kalogeropoulos D, Sakkas H, Mohammed B, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022;42:295-321.
2. Delair E, Latkany P, Noble AG, Rabiah P, McLeod R, Brezin A. Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19:91-102.
3. Balasundaram MB, Andavar R, Palaniswamy M, Venkatapathy N. Outbreak of acquired ocular toxoplasmosis involving 248 patients. Arch Ophthalmol. 2010;128:28-32.
4. Atmaca LS, Simsek T, Batioglu F. Clinical features and prognosis in ocular toxoplasmosis. Jpn J Ophthalmol. 2004;48:386-391.
5. Pleyer U, Schluter D, Manz M. Ocular toxoplasmosis: recent aspects of pathophysiology and clinical implications. Ophthalmic Res. 2014;52:116-123.
6. Lachenmaier SM, Deli MA, Meissner M, Liesenfeld O. Intracellular transport of Toxoplasma gondii through the blood-brain barrier. J Neuroimmunol. 2011;232:119-130.
7. Grigg ME, Ganatra J, Boothroyd JC, Margolis TP. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis. 2001;184:633-639.
8. Roizen N, Kasza K, Karrison T, et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention
strategies. Pediatrics. 2006;118:e379-390.
9. Bowie WR, King AS, Werker DH, et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet. 1997;350:173-177.
10. Pichi F, Veronese C, Lembo A, et al. New appraisals of Kyrieleis plaques: a multimodal imaging study. Br J Ophthalmol. 2017;101:316-321.
11. Fish RH, Hoskins JC, Kline LB. Toxoplasmosis neuroretinitis. Ophthalmology. 1993;100:1177-1182.
12. Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:869-878.
13. Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis. 2002;185 Suppl 1:S73-82.
14. Maenz M, Schluter D, Liesenfeld O, Schares G, Gross U, Pleyer U. Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res. 2014;39:77-106.
15. Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115:517-523.
16. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:102-114.
17. Wilder HC. Toxoplasma chorioretinitis in adults. AMA Arch Ophthalmol. 1952;48:127-136.
18. Bosch-Driessen EH, Rothova A. Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. Br J Ophthalmol. 1998;82:858-860.
19. Garweg JG, Scherrer J, Wallon M, Kodjikian L, Peyron F. Reactivation of ocular toxoplasmosis during pregnancy. BJOG. 2005;112:241-242.
20. Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47:554-566.
21. Schoenberger SD, Kim SJ, Thorne JE, et al. Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017;124:382-392.
22. Holland GN. Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive Committee of the American Uveitis Society. Am J Ophthalmol. 1994;117:663-667.
23. Lau CH, Missotten T, Salzmann J, Lightman SL. Acute retinal necrosis features, management, and outcomes. Ophthalmology. 2007;114:756-762.
24. Cochrane TF, Silvestri G, McDowell C, Foot B, McAvoy CE. Acute retinal necrosis in the United Kingdom: results of a prospective surveillance study. Eye (Lond). 2012;26:370-377; quiz 378.
25. Palay DA, Sternberg P, Jr., Davis J, et al. Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy. Am J Ophthalmol. 1991;112:250-255.
26. Hillenkamp J, Nolle B, Bruns C, Rautenberg P, Fickenscher H, Roider J. Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology. 2009;116:1971-1975 e1972.
27. Port AD, Orlin A, Kiss S, Patel S, D’Amico DJ, Gupta MP. Cytomegalovirus Retinitis: A Review. J Ocul Pharmacol Ther. 2017;33:224-234.
28. Jabs DA, Ahuja A, Van Natta ML, et al. Long-term Outcomes of Cytomegalovirus Retinitis in the Era of Modern Antiretroviral Therapy: Results from a United States Cohort. Ophthalmology.
2015;122:1452-1463.
29. Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol. 2008;145:397-408.
30. D’Amico DJ, Talamo JH, Felsenstein D, Hirsch MS, Albert DM, Schooley RT. Ophthalmoscopic and histologic findings in cytomegalovirus retinitis treated with BW-B759U. Arch Ophthalmol.
1986;104:1788-1793.
31. Smith IL, Macdonald JC, Freeman WR, Shapiro AM, Spector SA. Cytomegalovirus (CMV) retinitis activity is accurately reflected by the presence and level of CMV DNA in aqueous humor
and vitreous. J Infect Dis. 1999;179:1249-1253.
32. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology. 1983;90:859-873.
33. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71:154-163.
34. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl
J Med. 1995;333:615-620.
35. Jacobson MA, O’Donnell JJ. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. J Acquir Immune Defic Syndr (1988). 1991;4 Suppl 1:S11-15.
36. Jabs DA, Ahuja A, Van Natta M, Dunn JP, Yeh S, Studies of the Ocular Complications of ARG. Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the
era of highly active antiretroviral therapy. Ophthalmology. 2013;120:1262-1270.
37. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthal-
mol. 2000;129:634-639.
38. Tsan GL, Claiborne RT. Ocular syphilis. Clin Exp Optom. 2021;104:756-759.
39. Kiss S, Damico FM, Young LH. Ocular manifestations and treatment of syphilis. Semin Ophthalmol. 2005;20:161-167.
40. Oliver SE, Cope AB, Rinsky JL, et al. Increases in Ocular Syphilis-North Carolina, 2014-2015. Clin Infect Dis. 2017;65:1676-1682.
41. Oliver GF, Stathis RM, Furtado JM, et al. Current ophthalmology practice patterns for syphilitic uveitis. Br J Ophthalmol. 2019;103:1645-1649.
42. Workowski KA, Bolan GA, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
43. Ghanem KG, Ram S, Rice PA. The Modern Epidemic of Syphilis. N Engl J Med. 2020;382:845-854.
44. Ksiaa I, Abroug N, Mahmoud A, et al. Update on Bartonella neuroretinitis. J Curr Ophthalmol. 2019;31:254-261.
45. Koehler JE, Glaser CA, Tappero JW. Rochalimaea henselae infection. A new zoonosis with the domestic cat as reservoir. JAMA. 1994;271:531-535.
46. Reed JB, Scales DK, Wong MT, Lattuada CP, Jr., Dolan MJ, Schwab IR. Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. Ophthalmology.
1998;105:459-466.
47. Cunningham ET, Koehler JE. Ocular bartonellosis. Am J Ophthalmol. 2000;130:340-349.
48. Biancardi AL, Curi AL. Cat-scratch disease. Ocul Immunol Inflamm. 2014;22:148-154.
49. Carithers HA, Margileth AM. Cat-scratch disease. Acute encephalopathy and other neurologic manifestations. Am J Dis Child. 1991;145:98-101.
50. Anderson BE, Neuman MA. Bartonella spp. as emerging human pathogens. Clin Microbiol Rev. 1997;10:203-219.
51. Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: review of the literature and new observations. J Neuroophthalmol. 2011;31:58-68.
52. Ray S, Gragoudas E. Neuroretinitis. Int Ophthalmol Clin. 2001;41:83-102.
53. Oray M, Onal S, Koc Akbay A, Tugal Tutkun I. Diverse Clinical Signs of Ocular Involvement in Cat Scratch Disease. Turk J Ophthalmol. 2017;47:9-17.
54. Eiger-Moscovich M, Amer R, Oray M, Tabbara KF, Tugal-Tutkun I, Kramer M. Retinal artery occlusion due to Bartonella henselae infection: a case series. Acta Ophthalmol. 2016;94:e367-370.
55. Gass JD. Diseases of the optic nerve that may simulate macular disease. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83:763-770.
56. Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J. 1992;11:474-478.
57. Tabbara KF. Ocular tuberculosis: anterior segment. Int Ophthalmol Clin. 2005;45:57-69.
58. Mansour AM, Haymond R. Choroidal tuberculomas without evidence of extraocular tuberculosis. Graefes Arch Clin Exp Ophthalmol. 1990;228:382-383.
59. Gupta V, Gupta A, Arora S, Bambery P, Dogra MR, Agarwal A. Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. Ophthalmology. 2003;110:1744-1749.
60. Bansal R, Gupta A, Gupta V, Dogra MR, Sharma A, Bambery P. Tubercular serpiginous-like choroiditis presenting as multifocal serpiginoid choroiditis. Ophthalmology. 2012;119:2334-2342.
61. Das T, Biswas J, Kumar A, et al. Eales’ disease. Indian J Ophthalmol. 1994;42:3-18.
ENDOFTALMİLER
KAYNAKLAR
1. Dickey JB, Thompson KD, Jay WM. Anterior chamber aspirate cultures after uncomplicated cataract surgery. Am J Ophthalmol. 1991;112(3):278-282. doi:10.1016/s0002-9394(14)76728-5
2. Garg P, Roy A, Sharma S. Endophthalmitis after cataract surgery: epidemiology, risk factors, and evidence on protection. Curr Opin Ophthalmol. 2017;28(1):67-72. doi:10.1097/
ICU.0000000000000326
3. Schwartz SG, Flynn HW Jr, Grzybowski A, Relhan N, Ferris FL 3rd. Intracameral Antibiotics and Cataract Surgery: Endophthalmitis Rates, Costs, and Stewardship. Ophthalmology.
2016;123(7):1411-1413. doi:10.1016/j.ophtha.2016.03.024
4. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology. 1991;98(5):639-650.
doi:10.1016/s0161-6420(91)32239-5
5. Levin HJ, Mehta MS, Storey PP, et al. Endophthalmitis following cataract surgery: visual outcomes, microbial spectrum and complications. Curr Opin Ophthalmol. 2023;34(3):237-242.
doi:10.1097/ICU.0000000000000951
6. Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management [published correction appears in Retina. 2007 Sep;27(7):table of contents. Dosage error in article
text]. Retina. 2007;27(6):662-680. doi:10.1097/IAE.0b013e3180323f96
7. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study [published correction appears in Am J Ophthalmol
1996 Dec;122(6):920]. Am J Ophthalmol. 1996;122(1):1-17. doi:10.1016/s0002-9394(14)71959-2
8. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98(12):1769-1775. doi:10.1016/s0161-6420(91)32052-9
9. Apt L, Isenberg SJ, Yoshimori R, Spierer A. Outpatient topical use of povidone-iodine in preparing the eye for surgery. Ophthalmology. 1989;96(3):289-292. doi:10.1016/s0161-6420(89)32897-
1
10. Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter
study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978-988. doi:10.1016/j.jcrs.2007.02.032
11. Yu-Wai-Man P, Morgan SJ, Hildreth AJ, Steel DH, Allen D. Efficacy of intracameral and subconjunctival cefuroxime in preventing endophthalmitis after cataract surgery. J Cataract Refract
Surg. 2008;34(3):447-451. doi:10.1016/j.jcrs.2007.10.041
12. Taban M, Behrens A, Newcomb RL, Nobe MY, McDonnell PJ. Incidence of acute endophthalmitis following penetrating keratoplasty: a systematic review. Arch Ophthalmol. 2005;123(5):605-
609. doi:10.1001/archopht.123.5.605
13. Krachmer JHI, Mannis MJ, Holland EJ. Cornea. St. Louis, Mo.: Mosby/ Elsevier; 2011. [Google Scholar] 14. Vislisel JM, Goins KM, Wagoner MD, et al. Incidence and Outcomes of Positive Donor Corneoscleral Rim Fungal Cultures after Keratoplasty. Ophthalmology. 2017;124(1):36-42. do-
i:10.1016/j.ophtha.2016.09.017
15. Vajpayee RB, Sharma N, Sinha R, Agarwal T, Singhvi A. Infectious keratitis following keratoplasty. Surv Ophthalmol. 2007;52(1):1-12. doi:10.1016/j.survophthal.2006.10.001
16. Davila JR, Mian SI. Infectious keratitis after keratoplasty. Curr Opin Ophthalmol. 2016;27(4):358-366. doi:10.1097/ICU.0000000000000269
17. Lomholt JA, Baggesen K, Ehlers N. Recurrence and rejection rates following corneal transplantation for herpes simplex keratitis. Acta Ophthalmol Scand. 1995;73(1):29-32. do-
i:10.1111/j.1600-0420.1995.tb00008.x
18. Perez-Straziota C, Randleman JB. Femtosecond-assisted LASIK: Complications and Management. Int Ophthalmol Clin. 2016;56(2):59-66. doi:10.1097/IIO.0000000000000105
19. Akova YA, Onat M, Koc F, et al. Microbial keratitis following penetrating keratoplasty. Ophthalmic Surg Lasers 1999; 30:449–455.
20. Vajpayee RB, Boral SK, Dada T, et al. Risk factors for graft infection in India: a case-control study. Br J Ophthalmol 2002; 86:261–265.
21. Khodadoust AA, Franklin RM. Transfer of bacterial infections by donor cornea in penetrating keratoplasty. Am J Ophthalmol 1979; 87:130–132.
22. DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002;120(3):297-
300. doi:10.1001/archopht.120.3.297
23. Allingham RR, Dmji KF, Freedman S, et al. Shields’ Textbook of Glaucoma. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
24. Brown RH, Yang LH, Walker SD, Lynch MG, Martinez LA, Wilson LA. Treatment of bleb infection after glaucoma surgery. Arch Ophthalmol. 1994;112(1):57-61. doi:10.1001/archop-
ht.1994.01090130067019
25. Soltau JB, Rothman RF, Budenz DL, et al. Risk factors for glaucoma filtering bleb infections. Arch Ophthalmol. 2000;118(3):338-342. doi:10.1001/archopht.118.3.338
26. Lehman OJ, Bunce C, Matheson MM, et al. Risk factors for development of post-trabeculectomy endophthalmitis. Br J Ophthalmol. 2000;84:1349-1353.
27. Burnstein AL, WuDunn D, Knotts SL, Catoira Y, Cantor LB. Conjunctival advancement versus nonincisional treatment for late-onset glaucoma filtering bleb leaks. Ophthalmology.
2002;109(1):71-75. doi:10.1016/s0161-6420(01)00838-7
28. Budenz DL, Chen PP, Weaver YK. Conjunctival advancement for late-onset filtering bleb leaks: indications and outcomes. Arch Ophthalmol. 1999;117(8):1014-1019. doi:10.1001/archop-
ht.117.8.1014
29. Greenfield DS, Suñer IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996;114(8):943-949. doi:10.1001/
archopht.1996.01100140151007
30. Solus JF, Jampel HD, Tracey PA, et al. Comparison of limbus-based and fornix-based trabeculectomy: success, bleb-related complications, and bleb morphology. Ophthalmology.
2012;119(4):703-711. doi:10.1016/j.ophtha.2011.09.046
31. Reynolds AC, Skuta GL, Monlux R, Johnson J. Management of blebitis by members of the American Glaucoma Society: a survey. J Glaucoma. 2001;10(4):340-347. doi:10.1097/00061198-
200108000-00015
32. Chen PP, Gedde SJ, Budenz DL, Parrish RK 2nd. Outpatient treatment of bleb infection. Arch Ophthalmol. 1997;115(9):1124-1128. doi:10.1001/archopht.1997.01100160294005
33. Song A, Scott IU, Flynn HW Jr, Budenz DL. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology. 2002;109(5):985-991. doi:10.1016/
s0161-6420(02)00965-x
34. Busbee BG, Recchia FM, Kaiser R, Nagra P, Rosenblatt B, Pearlman RB. Bleb-associated endophthalmitis: clinical characteristics and visual outcomes. Ophthalmology. 2004;111(8):1495-1503.
doi:10.1016/j.ophtha.2004.01.028
35. Poulsen EJ, Allingham RR. Characteristics and risk factors of infections after glaucoma filtering surgery. J Glaucoma. 2000;9(6):438-443. doi:10.1097/00061198-200012000-00004
36. Leng T, Miller D, Flynn HW Jr, Jacobs DJ, Gedde SJ. Delayed-onset bleb-associated endophthalmitis (1996-2008): causative organisms and visual acuity outcomes. Retina. 2011;31(2):344-352.
doi:10.1097/IAE.0b013e3181e09810
37. Kattan HM, Flynn HW Jr, Pflugfelder SC, Robertson C, Forster RK. Nosocomial endophthalmitis survey. Current incidence of infection after intraocular surgery. Ophthalmology.
1991;98(2):227-238.
38. Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology.
1998;105(6):1004-1010. doi:10.1016/S0161-6420(98)96000-6
39. Dave VP, Pathengay A, Schwartz SG, Flynn HW Jr. Endophthalmitis following pars plana vitrectomy: a literature review of incidence, causative organisms, and treatment outcomes. Clin
Ophthalmol. 2014;8:2183-2188. Published 2014 Oct 31. doi:10.2147/OPTH.S71293
40. Gokce G, Sobaci G, Ozgonul C. Post-Traumatic Endophthalmitis: A Mini-Review. Semin Ophthalmol. 2015;30:470-474.
41. Kuhn F, Maisiak R, Mann L, Mester V, Morris R, Witherspoon CD. The Ocular Trauma Score (OTS). Ophthalmol Clin North Am. 2002;15:163-165, vi.
42. Cornut PL, Youssef el B, Bron A, et al. A multicentre prospective study of post-traumatic endophthalmitis. Acta Ophthalmol. 2013;91:475-482.
43. Lieb DF, Scott IU, Flynn HW, Jr., Miller D, Feuer WJ. Open globe injuries with positive intraocular cultures: factors influencing final visual acuity outcomes. Ophthalmology. 2003;110:1560-
1566.
44. Bhagat N, Nagori S, Zarbin M. Post-traumatic Infectious Endophthalmitis. Surv Ophthalmol. 2011;56:214-251.
45. Thompson JT, Parver LM, Enger CL, Mieler WF, Liggett PE. Infectious endophthalmitis after penetrating injuries with retained intraocular foreign bodies. National Eye Trauma System.
Ophthalmology. 1993;100:1468-1474.
46. Zhang Y, Zhang MN, Jiang CH, Yao Y, Zhang K. Endophthalmitis following open globe injury. Br J Ophthalmol. 2010;94:111-114.
47. Erdurman FC, Hurmeric V, Gokce G, Durukan AH, Sobaci G, Altinsoy HI. Ocular injuries from improvised explosive devices. Eye (Lond). 2011;25:1491-1498.
48. Sobaci G, Akyn T, Mutlu FM, Karagul S, Bayraktar MZ. Terror-related open-globe injuries: a 10-year review. Am J Ophthalmol. 2005;139:937-939.
49. Al-Omran AM, Abboud EB, Abu El-Asrar AM. Microbiologic spectrum and visual outcome of posttraumatic endophthalmitis. Retina. 2007;27:236-242.
50. Gupta A, Srinivasan R, Kaliaperumal S, Saha I. Post-traumatic fungal endophthalmitis–a prospective study. Eye (Lond). 2008;22:13-17.
51. Ahmed Y, Schimel AM, Pathengay A, Colyer MH, Flynn HW, Jr. Endophthalmitis following open-globe injuries. Eye (Lond). 2012;26:212-217.
52. Yang CS, Lu CK, Lee FL, Hsu WM, Lee YF, Lee SM. Treatment and outcome of traumatic endophthalmitis in open globe injury with retained intraocular foreign body. Ophthalmologica.
2010;224:79-85.
53. Chee SP, Jap A. Endogenous endophthalmitis. Curr Opin Ophthalmol. 2001;12:464-470.
54. Okada AA, Johnson RP, Liles WC, D’Amico DJ, Baker AS. Endogenous bacterial endophthalmitis. Report of a ten-year retrospective study. Ophthalmology. 1994;101:832-838.
55. Wong JS, Chan TK, Lee HM, Chee SP. Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction. Ophthalmology. 2000;107:1483-1491.
56. Brod RD, Flynn HW, Jr., Clarkson JG, Pflugfelder SC, Culbertson WW, Miller D. Endogenous Candida endophthalmitis. Management without intravenous amphotericin B. Ophthalmology.
1990;97:666-672; disc: 672-664.
57. Greenwald MJ, Wohl LG, Sell CH. Metastatic bacterial endophthalmitis: a contemporary reappraisal. Surv Ophthalmol. 1986;31:81-101.
58. Huth A, Roth M, Viestenz A. [Endogenous Candida endophthalmitis]. Ophthalmologie. 2024;121:272-281.
59. Weishaar PD, Flynn HW, Jr., Murray TG, et al. Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes. Ophthalmology. 1998;105:57-65.
60. Virata SR, Kylstra JA, Brown JC, Wohl DA, Cohen MS. Worsening of endogenous Candida albicans endophthalmitis during therapy with intravenous lipid complex amphotericin B. Clin
Infect Dis. 1999;28:1177-1178.
OKÜLER TOKSOKARİAZİS
KAYNAKLAR
1. Woodhall D, Starr MC, Montgomery SP, Jones JL, Lum F, Read RW, Moorthy RS. Ocular toxocariasis: epidemiologic, anatomic, and therapeutic variations based on a survey of ophthalmic
subspecialists. Ophthalmology. 2012 Jun;119(6):1211-7
2. Stewart JM, Cubillan LD, Cunningham ET. Prevalence, clinical features, and causes of vision loss among patients with ocular toxocariasis. Retina. 2005 Dec;25(8):1005-13
3. Schantz PM, Meyer D, Glickman LT. Clinical, serologic, and epidemiologic characteristics of ocular toxocariasis. Am J Trop Med Hyg. 1979 Jan;28(1):24-8
4. Natesh S, K H, Nair U, Nair K. Subretinal worm and repeat laser photocoagulation. Middle East Afr J Ophthalmol. 2010 Apr;17(2):183-5